GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
- First Posted Date
- 2005-02-18
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 600
- Registration Number
- NCT00103922
- Locations
- πΊπΈ
GSK Investigational Site, Milwaukee, Wisconsin, United States
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 282
- Registration Number
- NCT00103727
- Locations
- πΊπΈ
GSK Investigational Site, Richmond, Virginia, United States
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
- First Posted Date
- 2005-02-09
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT00103454
- Locations
- π¨π¦
GSK Investigational Site, Saskatoon, Saskatchewan, Canada
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
- Conditions
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 547
- Registration Number
- NCT00102882
- Locations
- π΅π·
GSK Investigational Site, Ponce, Puerto Rico
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)
- Conditions
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 99
- Registration Number
- NCT00102739
- Locations
- π¬π§
GSK Investigational Site, Swansea, United Kingdom
Study Of Asthma In Patients Of African Descent
- Conditions
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 479
- Registration Number
- NCT00102765
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 183
- Registration Number
- NCT00102726
- Locations
- π¬π§
GSK Investigational Site, Leicester, United Kingdom
Study Of GW679769 In Major Depressive Disorder
- Conditions
- First Posted Date
- 2005-01-31
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 356
- Registration Number
- NCT00102492
- Locations
- π¨π¦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
- Conditions
- First Posted Date
- 2005-01-19
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 741
- Registration Number
- NCT00101985
- Locations
GSK Investigational Site
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
- Conditions
- First Posted Date
- 2005-01-19
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT00101946
- Locations
- π¨π¦
GSK Investigational Site, Quebec, Canada